| C27 | Uptake of oral pre-exposure prophylaxis for HIV infection among men who have sex with men and transgender: lessons learned during the SARS-CoV-2 pandemic from the first PrEP project in Myanmar | On-demand oral abstract session | PrEP |
| C27 | HIV risk behaviors among retail pharmacy clients seeking sexual and reproductive health services in Kenya | On-demand oral abstract session | PrEP |
| C27 | STI incidence among participants in the HIV Pre-exposure Prophylaxis (PrEP) impact trial in England | On-demand oral abstract session | PrEP |
| C27 | Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trial | Oral abstract session with live Q&A | PrEP |
| C27 | Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase | Oral abstract session with live Q&A | PrEP |
| C27 | Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US | Oral abstract session with live Q&A | PrEP |
| C27 | Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW | Oral abstract session with live Q&A | PrEP |
| C27 | HIV pre-exposure prophylaxis amongst most-at-risk populations in Cameroon: lessons learnt from the CHAMP project | E-poster | PrEP |
| C27 | Substantial increase in HIV risk behaviors and poor PrEP adherence among men who have sex with men during the COVID-19 pandemic: an observational longitudinal study in four cities of China | E-poster | PrEP |
| C27 | Acceptability of and preferences for long-acting injectable PrEP (LAI-PrEP) and other PrEP modalities among sexual minority men in Nigeria, Africa | E-poster | PrEP |